168 related articles for article (PubMed ID: 31571056)
1. High Stromal TGFBI in Lung Cancer and Intratumoral CD8-Positive T Cells were Associated with Poor Prognosis and Therapeutic Resistance to Immune Checkpoint Inhibitors.
Nakazawa N; Yokobori T; Kaira K; Turtoi A; Baatar S; Gombodorj N; Handa T; Tsukagoshi M; Ubukata Y; Kimura A; Kogure N; Ogata K; Maeno T; Sohda M; Yajima T; Shimizu K; Mogi A; Kuwano H; Saeki H; Shirabe K
Ann Surg Oncol; 2020 Mar; 27(3):933-942. PubMed ID: 31571056
[TBL] [Abstract][Full Text] [Related]
2. ASO Author Reflections: High Stromal TGFBI is a Useful Predictive Marker for Nivolumab in Non-small Cell Lung Cancer.
Nakazawa N; Yokobori T; Turtoi A; Shirabe K
Ann Surg Oncol; 2020 Mar; 27(3):943-944. PubMed ID: 31696394
[No Abstract] [Full Text] [Related]
3. Efficacy of immune checkpoint inhibitors according to PD-L1 tumor proportion scores in non-small cell lung cancer.
Park S; Choi YD; Kim J; Kho BG; Park CK; Oh IJ; Kim YC
Thorac Cancer; 2020 Feb; 11(2):408-414. PubMed ID: 31841269
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer.
Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
Lung Cancer; 2019 Nov; 137():56-63. PubMed ID: 31546072
[TBL] [Abstract][Full Text] [Related]
5. Tumor mutational load, CD8
Hurkmans DP; Kuipers ME; Smit J; van Marion R; Mathijssen RHJ; Postmus PE; Hiemstra PS; Aerts JGJV; von der Thüsen JH; van der Burg SH
Cancer Immunol Immunother; 2020 May; 69(5):771-777. PubMed ID: 32047958
[TBL] [Abstract][Full Text] [Related]
6. Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer.
Yoneda K; Kuwata T; Kanayama M; Mori M; Kawanami T; Yatera K; Ohguri T; Hisaoka M; Nakayama T; Tanaka F
Br J Cancer; 2019 Sep; 121(6):490-496. PubMed ID: 31388183
[TBL] [Abstract][Full Text] [Related]
7. Programmed Cell Death Ligand 1 Expression in Non-Small-cell Lung Cancer Patients With Interstitial Lung Disease: A Matched Case-control Study.
Fujimoto D; Sato Y; Morimoto T; Uehara K; Ito M; Otsuka K; Nagata K; Sakanoue I; Hamakawa H; Nakagawa A; Takahashi Y; Imai Y; Tomii K
Clin Lung Cancer; 2018 Sep; 19(5):e667-e673. PubMed ID: 29844002
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
[TBL] [Abstract][Full Text] [Related]
9. Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma.
Lee J; Choi Y; Jung HA; Lee SH; Ahn JS; Ahn MJ; Park K; Sun JM
Eur J Cancer; 2020 Jun; 132():150-158. PubMed ID: 32371248
[TBL] [Abstract][Full Text] [Related]
10. A Minimum Of 100 Tumor Cells in a Single Biopsy Sample Is Required to Assess Programmed Cell Death Ligand 1 Expression in Predicting Patient Response to Nivolumab Treatment in Nonsquamous Non-Small Cell Lung Carcinoma.
Naito T; Udagawa H; Sato J; Horinouchi H; Murakami S; Goto Y; Kanda S; Fujiwara Y; Yamamoto N; Zenke Y; Kirita K; Matsumoto S; Yoh K; Niho S; Motoi N; Ohe Y; Ishii G; Goto K
J Thorac Oncol; 2019 Oct; 14(10):1818-1827. PubMed ID: 31260834
[TBL] [Abstract][Full Text] [Related]
11. Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8
Peng DH; Rodriguez BL; Diao L; Chen L; Wang J; Byers LA; Wei Y; Chapman HA; Yamauchi M; Behrens C; Raso G; Soto LMS; Cuentes ERP; Wistuba II; Kurie JM; Gibbons DL
Nat Commun; 2020 Sep; 11(1):4520. PubMed ID: 32908154
[TBL] [Abstract][Full Text] [Related]
12. Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer.
Chae YK; Viveiros P; Lopes G; Sukhadia B; Sheikh MM; Saravia D; Florou V; Sokol ES; Frampton GM; Chalmers ZR; Ali SM; Ross JS; Chang S; Wang S; Chiec L; Rahbari A; Mohindra N; Villaflor V; Shin SH; Oh M; Anker J; Park LC; Wang V; Chuang J; Park W
J Thorac Oncol; 2019 Oct; 14(10):1807-1817. PubMed ID: 31238177
[TBL] [Abstract][Full Text] [Related]
13. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
14. Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy.
Liu Y; Zugazagoitia J; Ahmed FS; Henick BS; Gettinger SN; Herbst RS; Schalper KA; Rimm DL
Clin Cancer Res; 2020 Feb; 26(4):970-977. PubMed ID: 31615933
[TBL] [Abstract][Full Text] [Related]
15. Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.
Hendriks LEL; Henon C; Auclin E; Mezquita L; Ferrara R; Audigier-Valette C; Mazieres J; Lefebvre C; Rabeau A; Le Moulec S; Cousin S; Duchemann B; le Pechoux C; Botticella A; Ammari S; Gazzah A; Caramella C; Adam J; Lechapt E; Planchard D; De Ruysscher D; Dingemans AM; Besse B
J Thorac Oncol; 2019 Jul; 14(7):1244-1254. PubMed ID: 30780002
[TBL] [Abstract][Full Text] [Related]
16. Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria.
Liang H; Xu Y; Chen M; Zhong W; Wang M; Zhao J
Thorac Cancer; 2020 Apr; 11(4):1068-1075. PubMed ID: 32129934
[TBL] [Abstract][Full Text] [Related]
17. Pseudoprogression in Previously Treated Patients with Non-Small Cell Lung Cancer Who Received Nivolumab Monotherapy.
Fujimoto D; Yoshioka H; Kataoka Y; Morimoto T; Hata T; Kim YH; Tomii K; Ishida T; Hirabayashi M; Hara S; Ishitoko M; Fukuda Y; Hwang MH; Sakai N; Fukui M; Nakaji H; Morita M; Mio T; Yasuda T; Sugita T; Hirai T
J Thorac Oncol; 2019 Mar; 14(3):468-474. PubMed ID: 30468872
[TBL] [Abstract][Full Text] [Related]
18. Increased CD3+ T cells with a low FOXP3+/CD8+ T cell ratio can predict anti-PD-1 therapeutic response in non-small cell lung cancer patients.
Kim H; Kwon HJ; Han YB; Park SY; Kim ES; Kim SH; Kim YJ; Lee JS; Chung JH
Mod Pathol; 2019 Mar; 32(3):367-375. PubMed ID: 30297881
[TBL] [Abstract][Full Text] [Related]
19. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
[TBL] [Abstract][Full Text] [Related]
20. Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.
Toki MI; Mani N; Smithy JW; Liu Y; Altan M; Wasserman B; Tuktamyshov R; Schalper K; Syrigos KN; Rimm DL
J Thorac Oncol; 2018 Dec; 13(12):1884-1896. PubMed ID: 30267840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
